Thursday, October 15th, 2026
7am PDT / 10am EDT / 3pm BST / 4pm CEST

AI can now fold proteins, predict binding affinities and generate novel chemistry at remarkable speed. AI-discovered molecules are reaching the clinic faster and passing Phase I at rates well above historical norms. Yet in Phase II, where efficacy in patients is first properly tested, their success rate is broadly the same as the industry average. We have become much better at making molecules. We have not yet become much better at predicting which ones will work in humans.

In this webinar, hosted by DDW, two Evotec leaders look at what that pattern means for drug design.

Rui Wang, EVP and Head of Global In Silico and AI, will draw on the clinical record so far to argue that the next wave of value lies upstream of the molecule: the right target, in the right patients, backed by human-relevant evidence from multi-omics patient data and iPSC disease models.

Christophe Boldron, VP and Head of Molecular Architects, will show what this means in daily practice. Drawing on real-world deployment of AI/ML across integrated computational and medicinal chemistry teams, he will cover where AI tools genuinely change design decisions, where expert judgement still leads, and how closed design-make-test-analyse loops carry translational thinking into molecule optimisation.

Attendees will leave with a practical view of where AI reduces attrition today, where it does not yet, and what to build or partner for next. 

Q&A with the speakers follows the presentations.

Register now!

 

Supported by